Anti-GPRC5D nano antibody and application thereof

CN119698434APending Publication Date: 2025-03-25SHANDONG SIMCERE BIO PHARMA CO LTD
0 Cites 0 Cited by

Patent Information

Application Number
CN202380054788.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-07-21
Filing Date
2023-07-20
Publication Date
2025-03-25

AI Technical Summary

Technical Problem

In the current treatment of multiple myeloma, patients with BCMA negative or low BCMA expression are prone to relapse after receiving BCMA-targeted CAR-T cell therapy. There is a lack of effective treatment methods, and GPRC5D has not been fully developed as a potential target.

Method used

Develop a nanobody that specifically binds to G protein-coupled receptor C5 family subtype D (GPRC5D), and use its excellent binding ability to provide new treatment methods for patients with no or low expression of BCMA, and prepare corresponding antibodies. or antigen-binding fragments, multispecific antigen-binding molecules, nucleic acid fragments, vectors, host cells, pharmaceutical compositions, and therapeutic methods for the treatment of multiple myeloma.

Benefits of technology

It provides efficient binding ability to GPRC5D, significantly improves the survival rate and prognosis of relapsed patients treated with BCMA targets, and provides a new potential target for the treatment of multiple myeloma.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides an antibody aiming at G protein coupled receptor C5 family subtype D (GPRC5D) and application thereof. Specifically, the invention discloses a nano antibody specifically binding to GPRC5D or an antigen binding fragment thereof, a coding nucleic acid, an expression vector and an expression cell thereof, a preparation method, a pharmaceutical composition and application thereof in preparation of the pharmaceutical composition for treating diseases, such as tumor treatment. Compared with a full-length antibody, the nano antibody provided by the invention can be more effectively combined with the target protein of the antibody GPRC5D which is difficult to develop. The invention is of great significance to development of GPRC5D antibody therapeutic drugs and detection reagents.
Need to check novelty before this filing date? Find Prior Art